Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $297.3 million.

  • Taysha Gene Therapies' Cash & Equivalents rose 88.56% to $297.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.3 million, marking a year-over-year increase of 88.56%. This contributed to the annual value of $139.0 million for FY2024, which is 3.41% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Cash & Equivalents of $297.3 million as of Q3 2025, which was down 4.94% from $312.8 million recorded in Q2 2025.
  • Taysha Gene Therapies' Cash & Equivalents' 5-year high stood at $312.8 million during Q2 2025, with a 5-year trough of $36.9 million in Q3 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Cash & Equivalents value was $143.9 million (recorded in 2023), while the average stood at $157.9 million.
  • Over the last 5 years, Taysha Gene Therapies' Cash & Equivalents had its largest YoY gain of 344.68% in 2023, and its largest YoY loss of 36.11% in 2023.
  • Taysha Gene Therapies' Cash & Equivalents (Quarterly) stood at $87.9 million in 2022, then soared by 63.79% to $143.9 million in 2023, then decreased by 3.41% to $139.0 million in 2024, then surged by 88.56% to $297.3 million in 2025.
  • Its Cash & Equivalents was $297.3 million in Q3 2025, compared to $312.8 million in Q2 2025 and $116.6 million in Q1 2025.